Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Results available

Sirolimus for Advanced Age-Related Macular Degeneration

NCT01445548
Conditions
Age-Related Macular Degeneration, Geographic Atrophy
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
56 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Completed Phase 2 Interventional Results available

Adult Attention Deficit Hyperactivity Disorder

NCT01692782
Conditions
Adult Attention Deficit Hyperactivity Disorder
Interventions
SEP-225289, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Encino, California • Garden Grove, California • Irvine, California + 28 more
Conditions
Acute Lymphoblastic Leukemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate, Lisdexamfetamine, Atomoxetine, Amphetamine, Dextroamphetamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
430,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Conditions
Anxiety, Wellness, Psychological, Overweight or Obesity, Hypertension, Prehypertension, Low Physical Fitness
Interventions
Fit2Lead Group 1-2
Behavioral
Lead sponsor
Duke University
Other
Eligibility
12 Years to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2028
U.S. locations
1
States / cities
Miami, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Sleep Management in Cancer Survivors

NCT00935376
Conditions
Insomnia
Interventions
Sleep Education Program, Mind-Body Bridging Program, Mindfulness Meditation Program
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Not listed No phase listed Observational Accepts healthy volunteers

"Immunomodulation in GWI (Phlebotomy)"

NCT04058275
Conditions
Gulf War Illness
Interventions
Draw blood (phlebotomy, 83 ml)
Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Stanford, California
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Cryoballoon Ablation
Device
Lead sponsor
Pentax Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Rochester, New York • Pittsburgh, Pennsylvania
Conditions
Carcinoma
Interventions
Sorafenib 100 mg (50-mg tablet), Sorafenib 200 mg (50-mg tablet), Sorafenib 400 mg (50-mg tablet), Sorafenib 400 mg (200-mg tablet), Sorafenib 400 mg (Expansion)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee • Madison, Wisconsin
Conditions
Depression, Post-Traumatic Stress Disorder, Functional Status
Interventions
Vets Prevail
Behavioral
Lead sponsor
Prevail Health Solutions, LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma
Interventions
First-line therapy, Second-line Multiple Myeloma treatments
Other · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
3,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
252
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 211 more
Conditions
Rhinovirus
Interventions
Nasal Swab Healthy Surveillance, Nasal Swab Sick Samples, Nasal Swab Hospitalized Cohort, Sick Follow-up Survey, Older Cohort Control Group, Procedural Comfort or Care
Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Up to 17 Years
Enrollment
670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Dementia
Interventions
Sleep Education Program
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Crohn's Disease
Interventions
Vorinostat, Ustekinumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder Disorder
Interventions
dasotraline
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Atlanta, Georgia + 2 more
Completed Phase 2Phase 3 Interventional

Dasotraline Pediatric ADHD Study

NCT02428088
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Dasotraline, Placebo Comparator
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
43
States / cities
Dothan, Alabama • National City, California • Paramount, California + 37 more
Conditions
EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Bevacizumab, Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Biological · Drug · Other
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
19
States / cities
La Jolla, California • Decatur, Illinois • Peoria, Illinois + 16 more
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Advanced Care Planning, Shared Decision Making, Video Decision Aids, Communication Skills, Advance Directives, Natural Language Processing, Covid19
Interventions
VitalTalk communication skills training, ACP Decisions Video Program, Intervention training:, Medical Record Review
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
42,019 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Hyde Park, New York
Conditions
Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Completed Phase 2 Interventional Results available

A Study in Participants With Acute Leukemia

NCT01214603
Conditions
Leukemia
Interventions
LY2090314
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Durham, North Carolina + 1 more
Conditions
Schizophrenia
Interventions
KarXT (xanomeline and trospium)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
6,876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Trelegy Ellipta, Stiolto Respimat, Tiotropium + Olodaterol (5/5 mcg), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
9,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
White Plains, New York